The sole question on appeal was whether it would have been obvious to make zolmitriptan into a nasal spray. The Federal Circuit agreed with the district court that the prior art taught away from formulating zolmitriptan for intranasal administration.
The post Nasal Spray Patents Covering Migraine Drug Zomig Not Invalid As Obvious appeared first on IPWatchdog.com | Patents & Patent Law.
Recent Posts
- Other Barks & Bites for Friday, April 4: CAFC Corrects Date of Public Accessibility in Trade Secret Appeal; Sixth Circuit Issues Divided Opinion in Data Privacy Appeal; and OpenAI Urges Broad Copyright Exception in UK
- Federal Circuit Tells Patent Applicant Expired Patents Don’t Get Provisional Rights Either
- Senate Judiciary Committee to Consider Bills Targeting Pharma Patents and Pricing
- USPTO Acting Director Expands on Reasoning for New Interim PTAB ‘Workload Management’ Process
- Strong IP Protections are the Key to Growing U.S. Manufacturing